{"task_id": "6e72b255319fdd65", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 168/464)", "text": "r age (especially >75),\n156\nHypercoagulable States\n\n--- Page 178 ---\nrecent surgery or trauma, immobility or paresis,\nBMI >30 kg/m2, central venous catheterization,\ninherited or acquired thrombophilic states, var\nicose veins, estrogen therapy\n\u0002\nINTERVENTIONS\nearly ambulation and exercises\ninvolving foot extension for all patients. Specific\nprophylaxis regimens include heparin 5000 U SC\nq8h, enoxaparin 40 mg SC daily, dalteparin 5000 U\nSC daily, or fondaparinux 2.5 mg SC daily. For\npatients at high risk for bleeding, consider non phar\nmacologic measures such as graduated compression\nstockings and pneumatic compression devices\nNEJM 2007 365:14\nRISK REDUCTION BY ANTICOAGULATION\n\u0002\nACUTE VTE EPISODE\nwithout anticoagulation, the\nrisk for recurrent DVT is 50% and for PE is 50%.\nWarfarin # risk to 8 10% by 1 month and 4 5% by\n3 months\n\u0002 VTE WITH LONG-TERM RISK FACTORS\nrecurrent DVT\nrisk 15%/year. Warfarin # risk to 3%\n\u0002 VTE IN PATIENTS WITH CANCER\nrisk of recurrence at\n6 months 17% with warfarin and 9% with dalte\nparin 200 IU/kg for 3 weeks, followed by 150 IU/kg\nfor at least 6 months\n\u0002 AF WITH PREVIOUS STROKE\nrecurrent stroke risk\n12%/year. ASA # risk to 10%/year. Warfarin # risk\nto 4%/year\n\u0002 AF WITH OTHER RISK FACTORS\nrecurrent stroke 8%/\nyear. ASA # risk to 4%/year. Warfarin # risk to 2%/\nyear\n\u0002\nLONE AF\nrecurrent stroke risk 1 2%/year. ASA or\nwarfarin # risk to < 1%/year\nMECHANICAL HEART VALVE\nrecurrent arterial\nembolic risk 4%/year. ASA # risk to 2%. Warfarin #\nrisk to 0.7 1%/year. Mitral valve prostheses 2\u0003 risk of\naortic valve prostheses. INR 2 3 for bileaflet or tilting\ndisc mechanical valves and 2.5 3.5 for caged ball or\ncaged disc valves\nSPECIFIC ENTITIES\nANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS)\n\u0002\nPATHOPHYSIOLOGY\nantibody against phospholi\npids or cell surface proteins bound to anionic\nphospholipids. These include lupus anticoagulants,\nanticardiolipin antibody (false positive VDRL), and\nanti b2GP1 (b2 glycoprotein 1) antibody ! may\nlead to hypercoagulable state and may rarely inhi\nbit coagulation\n\u0002\nCAUSES\nprimary APS, secondary APS (various\nrheumatic diseases such as SLE and infections\nsuch as HIV and drugs)\n\u0002\nCLINICAL FEATURES\nvenous and arterial thrombosis\nand rarely hemorrhage affecting the lungs, heart,\nCNS, GI, kidneys, skin, and eyes. Also recurrent fetal\nSPECIFIC ENTITIES (CONT\u2019D)\nlosses (recurrent first trimester or single late term),\nthrombocytopenia, and livedo reticularis\n\u0002\nDIAGNOSIS\nclinical criteria include thrombosis\n(\u00061 arterial, venous, or small vessel thrombosis\nin any organ) or pregnancy complications (\u00061\nunexplained deaths of morphologically normal\nfetus at or after the 10th week of gestation, \u00061\npremature births of morphologically normal neo\nnate at or before the 34th week of gestation, or \u00063\nunexplained consecutive spontaneous abortions\nbefore the 10th week of gestation). Laboratory\ncriteria include anticardiolipin antibodies (IgG or\nIgM at moderate or high levels on \u00062 occasions at\nleast 6 weeks apart) or the presence of a lupus\nanticoagulant (\u00062 occasions at least 6 weeks\napart). Diagnosis requires at least one clinical and\none laboratory criteria (sens 70%, spc 98%)\n\u0002\nCATASTROPHIC\nANTIPHOSPHOLIPID\nSYNDROME\nacute and devastating syndrome with multiple\nsimultaneous vascular occlusions throughout the\nbody, affecting mainly small vessels of kidney,\nlungs, CNS, heart, and skin. May be associated\nwith DIC, ARDS, cerebral and myocardial micro\ninfarctions. May be precipitated by infections,\nsurgery, and withdrawal of anticoagulation.\nTreatment consists of a combination of anticoa\ngulation, steroids, plasmapheresis, and/or IVIG.\nMortality rate is 50%\n\u0002\nTREATMENTS\nprimary prophylaxis for thrombosis\nis not indicated in persons with incidentally dis\ncovered antiphospholipid antibodies or lupus\nanticoagulants. Treatment of thromboses (both\nvenous and arterial) is indefinite warfarin antic\noagulation targeting an INR of 2 3. See p. 414 for\nmanagement of APS in pregnancy\nPAROXYSMAL NOCTURNAL HEMOGLOBINURIA\n(PNH)\n\u0002\nPATHOPHYSIOLOGY\nmutation in PIG A gene coding\nfor GPI anchor ! # GPI linked proteins such as\nCD59 (membrane attack complex inhibitory factor)\nand CD55 (decay accelerating factor) ! comple\nment mediated lysis of RBC ! acute renal failure\ndue to hemoglobulinuria, chronic renal failure due\nto iron deposits. Also \" platelet activation due to\ncomplements, tissue damage with \" tissue factor,\n# fibrinolysis ! \" thrombosis\n\u0002\nCLINICAL FEATURES\nhemolysis, thrombosis (hepa\ntic vein, portal vein, splenic vein, renal vein), mar\nrow aplasia, MDS, leukemia, infections, esophageal\nspasm, sexual dysfunction\n\u0002\nDIAGNOSIS\nflow cytometry, historically, Ham\u2019s test\n(RBC sensitivity to acidity)\n\u0002\nTREATMENTS\nsteroids,\nallogeneic\nstem\ncell\ntransplant\nTREATMENT ISSUES (CONT\u2019D)\nHypercoagulable States\n157", "text_length": 4785, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 168/464)", "type": "chunk", "chunk_index": 167, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.476862", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.477626", "status": "complete", "chunks_added": 3}